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Abstract (250 words) 
Purpose: To investigate whether demographic, clinical and treatment-related risk factors known 
at treatment initiation can be used to reliably predict future hormonal therapy non-persistence in 
women with breast cancer, to inform intervention development. 
 
Methods: Women with stage I-III breast cancer diagnosed 2000-2012 and prescribed hormonal 
therapy were identified from the National Cancer Registry Ireland (NCRI) and linked to 
pharmacy claims data from Ireland's Primary Care Reimbursement Services (PCRS). Non-
persistence was defined as a treatment gap of ≥180 days within 5 years of initiation. Seventeen 
demographic, clinical and treatment-related risk factors, identified from a systematic review, 
were abstracted from the NCRI-PCRS dataset. Multivariate binomial models were used to 
estimate relative risks (RR) and risk differences (RD) for associations between risk factors and 
non-persistence. Calibration and discriminative performance of the models were assessed. The 
analysis was repeated for early non-persistence (<1 year of initiation). 
 
Results: Within 5 years of treatment initiation 680 women (19.9%) were non-persistent. Women 
aged <50 years (adjusted RR 1.41, 95%CI 1.16-1.70) and those prescribed antidepressants 
(RR 1.22, 95%CI 1.04-1.45) had increased risk of non-persistence. Married women (RR 0.82 
95%CI 0.71-0.94) and those with prior medication use (RR 0.62 95%CI 0.51-0.75) had reduced 
risk of non-persistence. The area under the receiver-operating characteristic (ROC) curve for 
non-persistence was 0.61. Findings were similar for early non-persistence. 
 
Conclusion: The risk prediction model did not discriminate well between women at higher and 
lower-risk of non-persistence at treatment initiation. Future studies should consider other 
factors, such as psychological characteristics and experience of side-effects. 
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Introduction 
Clinical guidelines recommend that women with hormone receptor positive breast cancer 
receive at least five, and up to 10, years of adjuvant hormonal therapy as a preventative 
measure for breast cancer recurrence and mortality.(1, 2)  Reduced hormonal therapy exposure 
in women with breast cancer, due to either early treatment discontinuation (non-persistence) or 
failure to take the correct dosage at the prescribed frequency (non-adherence), has been shown 
to be associated with an increased risk of early breast cancer recurrence and mortality.(3-5) 
Despite clear clinical efficacy, non-persistence and non-adherence are both common. Rates of 
non-persistence at 5 years range from 16% to 32% in clinical trials of hormonal treatment and 
between 31% and 73% in routine clinical settings, while prevalence of non-adherence ranges 
from 41% to 72%.(6, 7)   
 
Despite the high prevalence of hormonal therapy non-adherence and non-persistence, the risk 
factors associated with hormonal therapy medication taking behaviour (MTB) have not been 
established. Recent systematic reviews have identified extremes of age (i.e. older and younger), 
follow-up care with a general practitioner (compared to follow-up by an oncologist) and 
experience of treatment side-effects as largely negatively associated with persistence, while 
taking more medications at baseline has been positively associated with persistence.(7, 8) 
However, for the majority of risk factors examined to date (e.g. chemotherapy, breast cancer 
stage) findings have either been mixed or null.(7, 8) Moreover, information on many of these risk 
factors is not readily available to the treating oncologist, and therefore has limited applicability in 
clinical practice in terms of helping to identify those women at risk of future non-persistence. A 
more thorough understanding of the contribution of demographic, clinical and treatment-related 
risk factors, which are readily available to the treating oncologist, to hormonal therapy MTB may 
help identify subgroups of women at higher risk of non-adherence or non-persistence at 
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treatment initiation. These women may benefit from an early intervention or additional support to 
persist with treatment. Knowledge of these risk factors at treatment initiation may also be used 
to develop a risk prediction tool for oncologists, which would have the potential to support 
clinical-decision making and could be used to estimate and communicate the risk of hormonal 
therapy non-persistence to women with breast cancer.(9) 
 
Developing interventions that can optimise hormonal therapy MTB in women with breast cancer 
is an important challenge. Any such interventions are likely to be resource intensive and costly 
and therefore need to be targeted at women at higher risk of non-adherence or non-persistence. 
The aim of this study was to investigate whether demographic, clinical and treatment-related 
risk factors, available at treatment initiation can be used to reliably predict hormonal therapy 
non-persistence in women with stage I-III breast cancer to help inform the development of 
targeted interventions.  
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Methods 
Setting & Data Source 
The study was conducted using individual-level patient records from the National Cancer 
Registry Ireland (NCRI), which have been linked to pharmacy claims data from Ireland's Primary 
Care Reimbursement Services (PCRS). These linked data have been described previously.(3) 
The NCRI database records detailed demographic and clinical information for all incident 
cancers diagnosed in the population usually resident in Ireland. Completeness of registration is 
high, especially for breast cancer.(10) The PCRS database records details of claims from 
pharmacies for financial reimbursement of medications dispensed to approximately one third 
(1.4 million) of the Irish population who have eligibility for the General Medical Services (GMS) 
scheme. Eligibility for the scheme (which provides free access to public health services and 
heavily subsidised prescribed medications) is assessed by a combination of means-test and 
age. The use for research of de-identified data held by the NCRI is covered by the Health 
(Provision of Information) Act 1997. 
Cohort Definition 
Our study cohort was defined as all women with a diagnosis of stage I-III, oestrogen (ER) or 
progesterone (PR) receptor positive breast cancer diagnosed 2001-2008, who had received 
tumour directed surgery and had subsequently filled at least one prescription for hormonal 
therapy (selective estrogen receptor modulator, SERM; aromatase inhibitor, AI) within one year 
of breast cancer diagnosis. Women also had to have GMS eligibility from one year prior to 
hormonal therapy initiation to at least the end of follow-up which was defined as the first of 
treatment discontinuation, disease recurrence, death or 5 years of completed hormonal therapy 
treatment. Women were excluded if they had previously been diagnosed with another invasive 
cancer other than non-melanoma skin cancer. Deaths (from all causes) were identified from 
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linked death certificates. Recurrences were identified from medical records by NCRI tumour 
registration officers and pathology reports of biopsied breast tumour metastases reported to the 
NCRI. Two separate cohorts of women were identified; women with a 5 year follow-up period 
and women with a 1 year follow-up period.  
Hormonal therapy MTB 
The date of dispensing, drug name and number of days’ supply on each prescription for 
hormonal therapy was identified from the PCRS database using WHO-ATC classifications for 
SERM and AI (Supplementary Table 1). This data was used to assemble a longitudinal daily 
history of hormonal therapy availability for each woman by assigning the days’ supply from each 
prescription to sequential days from the date of dispensing.(3, 11) These longitudinal histories 
were used to identify women who discontinued hormonal therapy within 5 years of initiating 
treatment. Treatment discontinuation (non-persistence) was defined as a gap in treatment of at 
least 180 days. We also calculated hormonal therapy adherence while on treatment as the 
proportion of days with a supply of hormonal therapy available up to the first of either treatment 
discontinuation or the end of follow-up (1 year or 5 years after initiation).(3) 
Risk factors for hormonal therapy MTB 
We previously conducted a systematic literature review to identify all risk factors that have been 
statistically significantly associated with hormonal therapy adherence or persistence.(8) 
(Supplementary Table 2) From these we selected demographic, clinical and treatment-related 
“baseline risk factors” i.e. factors which could, or would (in most settings), be assessed prior to, 
or at the time of, hormonal therapy initiation and are therefore likely to be routinely available to a 
prescriber/treating oncologist (Supplementary Table 2); for example, data collected during a 
“normal” medical history taking and examination.  
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Based on the baseline risk factors identified in our systematic review (Supplementary Table 2), 
we extracted the following demographic, clinical and treatment-related variables from the NCRI-
PCRS database: age at diagnosis (categorised as <50, 50-65, >65 for analysis); marital status; 
occupation; residential location(12); socioeconomic status, from a census-based deprivation 
score (5 levels ranging from least to most deprived)(13); smoking status; number of regular 
medications used prior to diagnosis (0, 1-4, ≥5); hormone replacement therapy (HRT) use prior 
to diagnosis; antidepressant use prior to hormonal therapy initiation; ER/PR status (ER+PR+, 
ER+PR-, ER-PR+); HER2 status (positive, negative, unspecified); tumor grade (low, 
intermediate, high, unspecified); lymph node status (positive, negative, unspecified); tumor size 
(<2cm, 2-5cm, >5cm, unspecified); receipt of surgery/radiation (mastectomy, breast conserving 
surgery with radiation, breast conserving surgery without radiation); receipt of chemotherapy; 
and type of hormonal therapy prescribed (SERM, AI). A small number (n=3) of baseline risk 
factors identified in our systematic review (Supplementary Table 2) were either not available in 
the NCRI-PCRS database or not applicable to our study cohort. 
Statistical Analysis 
Kaplan Meier plots were used to estimate the cumulative probability of hormonal therapy non-
persistence in the first five years of treatment with censoring at breast cancer recurrence or 
death. The distribution of demographic, clinical and treatment-related baseline risk factors was 
compared between women who completed five years of adjuvant hormonal therapy and women 
who did not using relative risks (RR) and risk differences (RD). Multivariate binomial models 
were used to estimate adjusted RR and RD (logit and identity link used respectively) with 95% 
confidence intervals (CI) for associations between all baseline risk factors and hormonal therapy 
non-persistence.(14, 15) The baseline risk factors were initially fitted individually then fitted 
simultaneously. 
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The performance of this model (Model 1: 5 year cohort) for predicting hormonal therapy non-
persistence prior to completing at least five years of treatment was evaluated. Firstly calibration 
was assessed by stratifying patients into predicted non-persistence risk deciles and plotting the 
observed proportions of non-persistence within each decile. Secondly the discriminative 
performance the model was assessed by the area under the receiver-operating characteristic 
(ROC) curve (AUC).(16)  
 
The possibility that demographic, clinical and treatment-related baseline risk factors would have 
a stronger influence on early treatment non-persistence was also considered and analyses were 
repeated for treatment non-persistence occurring only in the first year following treatment 
initiation (Model 2: 1 year cohort). Non-persistence was measured as a gap in treatment of ≥180 
days. Studies have indicated that the incidence and determinants of hormonal therapy non-
persistence may vary between early and later years of treatment.(6, 17, 18)  
 
All analyses were conducted using SAS® v9.3 (SAS® Institute Inc, Cary, NC) and results were 
considered statistically significant at a two-sided α-level of 0.05. 
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Results 
Cohort characteristics 
We identified 3,415 women from the linked NCRI-PCRS database with a diagnosis of stage I-III 
oestrogen (ER) or progesterone (PR) receptor positive breast cancer, who received tumour 
directed surgery followed by hormonal therapy with either a SERM or AI with a 5 year follow-up 
period. The median time from diagnosis to hormonal therapy initiation was 172 days (IQR; 66, 
223). The characteristics of these women are presented in Table 1. The mean age of women 
was 61.4 years (SD=12.6), and 52.3% of women were prescribed tamoxifen as their first 
hormonal therapy (Anastrazole 37.6%, Letrozole 9.8%, Exemestane 0.3%). We identified 6,609 
women from the linked NCRI-PCRS database with a 1 year follow-up period. The characteristics 
of these women are similar and presented in Table 2. 
Hormonal therapy MTB 
Within the 5 year follow-up cohort, we identified 680 women (19.9%) who stopped refilling 
prescriptions for their hormonal therapy prior to a breast cancer recurrence, death or completing 
at least five years of treatment. Women were followed for a total of 12,436 person years and the 
hormonal therapy discontinuation rate was 54.7 per 1000 woman years of hormonal therapy 
treatment. The cumulative probability of non-persistence at one, three, and five years after 
hormonal therapy initiation was 7.6% (95%CI 8.4%, 6.7%), 14.5% (95%CI 15.8%, 13.3%) and 
21.6% (95%CI 23.1%, 20.2%) respectively. In addition, we identified 390 (11.4%) women in our 
study population who were <80% adherent with treatment during the time that they were taking 
it. Overall, due to either non-persistence or non-adherence, 761 (22.3%) women received <80% 
of the doses required to complete five years of adjuvant hormonal therapy. 
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Within the 1 year follow-up cohort, 412 women (6.2%) stopped refilling prescriptions for their 
hormonal therapy prior to a breast cancer recurrence, death or completing at least one year of 
treatment and 742 (11.2%) were <80% adherent with treatment. In total, 997 (15.1%) women 
were either non-persistent or non-adherent within the first year of adjuvant hormonal therapy 
treatment.  
 
Validation & predictive ability of baseline risk factors for non-persistence  
Model 1: non-persistence within 5 years 
In multivariable Model 1, which included all of the previously identified demographic, clinical or 
treatment-related baseline risk factors, four baseline characteristics were statistically 
significantly associated with not completing 5 years of hormonal therapy (Table 1). Compared to 
women aged 50-65 years, women aged <50 years (adjusted RR 1.41 95% CI 1.16, 1.70), and 
women prescribed antidepressants (RR 1.22 95% CI 1.04, 1.45), were at significantly increased 
risk of non-persistence. Women who were married (RR 0.82 95% CI 0.71, 0.94) and women 
who had a history of medication use prior to their breast cancer diagnosis (>5 medications vs 
none: RR 0.61 95% CI 0.50, 0.75) had a significantly reduced risk of non-persistence. We found 
marginal, non-significant, associations with non-persistence for several other risk factors, 
including the type of surgery/radiation received (Table 1). Individually the risk factors were 
associated with up to a 7% increase (age <50 years) or 9% decrease (prior history of 
medication use) in the absolute risk of non-persistence (Table 1).  
 
The ROC curve for Model 1 is presented in Figure 1. The Hosmer-Lemeshow goodness of fit 
test was p=0.88. The AUC for this ROC curve was 0.61 which suggests not particularly good 
prediction of non-persistence with these baseline risk factors at 5 years.  
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Model 2: early non-persistence 
In Model 2, of all of the previously identified demographic, clinical or treatment-related baseline 
risk factors, three characteristics were statistically significantly associated with not completing 1 
year of hormonal therapy (Table 2). Compared to women aged 50-65 years, women aged >65 
years were at significantly increased risk of non-persistence (adjusted RR 1.45 95% CI 1.11, 
1.86). Similar to Model 1, women who were married (RR 0.79 95% CI 0.64, 0.96) and women 
who had a history of medication use prior to their breast cancer diagnosis (>5 medications vs. 
none: RR 0.36 95% CI 0.27, 0.48) had a significantly reduced risk of non-persistence (Table 2).  
The ROC curve for Model 2 is presented in Figure 2.  The results were similar to Model 1 and 
the AUC for the ROC curve was 0.63 (Figure 2). The Hosmer-Lemeshow goodness of fit test 
was p=0.86.  
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Discussion  
Summary of findings 
The aim of this study was to investigate whether demographic, clinical and treatment-related 
information likely to be routinely available at hormonal therapy initiation could be used to reliably 
predict non-persistence in women with stage I-III breast cancer. The development of such a risk 
prediction model would enable clinicians to identify at baseline women likely to be non-
persistent, to whom targeted support could be provided thereby maximising persistence and 
maximising clinical outcomes. However, only four of 17 previously identified risk factors (age, 
marital status, previous medication use and antidepressant use) were statistically significantly 
associated with completing five years of hormonal therapy. Moreover, our risk prediction model 
containing all risk factors did not discriminate well between women at high risk of hormonal 
therapy non-persistence at treatment initiation from those at lower risk. The same conclusion 
held when early non-persistence was considered (within 1 year of initiation). 
 
The rate of adjuvant hormonal therapy non-persistence in the current study (19.9%) at 5 years 
is somewhat lower than discontinuation rates of 31-73% and 47.1% by five years reported in 
previous studies.(7, 19) The definition of non-persistence in the current study was based on a 
gap of at least 6 months in filling prescriptions for hormonal therapy while previous studies have 
measured non-persistence using shorter refill gaps of 45-90 days in treatment.(20-22) Our rate 
of non-persistence was also adjusted for women who had stopped their hormonal therapy due 
to a breast cancer recurrence, which previous studies have not always done.   
 
In the current study, younger women (aged <50 years) had an increased risk of discontinuing 
hormonal therapy within 5 years, while older women (aged >65 years) had an increased risk of 
discontinuing hormonal therapy within 1 year.  Extremes of age (e.g. older and younger women) 
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have been shown to be largely negatively associated with hormonal therapy persistence and 
middle aged women (50-65 years) may be the most persistent.(7, 17, 23) Younger women have 
reported more difficulties in coping with breast cancer and more concerns over loss of fertility 
and femininity associated with hormonal therapy.(24) These concerns may also become less 
acceptable to younger women over time. Hormonal therapy side-effects have also been found 
to be associated with non-persistence in younger women during the later years of treatment (> 
16 months).(18) Early non-persistence in older women may be influenced by psychosocial 
factors such as lack of social support and a higher incidence of cognitive and functional 
impairment.(25)  There is some evidence of hormonal therapy having a negative influence on 
cognition within the first year of treatment and this may be more evident in older 
populations.(26)  
 
Women taking more medications at baseline had a reduced risk of hormonal therapy non-
persistence, findings similar to those of previous studies.(6, 17, 20, 27) Studies have also 
shown that patients who are medication naïve have a higher risk of non-persistence and the 
provision of aids (e.g. pill boxes) and action planning techniques (e.g. prompts or cues to take 
hormonal therapy) at treatment initiation may improve MTB.(28) Findings in previous studies 
were mixed for associations between marital status and antidepressant use and hormonal 
therapy persistence.(17, 18, 20) In the current study, married women had a reduced risk of 
hormonal therapy non-persistence within 1 and 5 years, while women prescribed 
antidepressants had an increased risk of non-persistence within 5 years. Marital status and 
social support have been reported to increase adherence to medical regimens in general, while 
depression is associated with reduced adherence.(29, 30) Spousal assistance may be 
associated with increased persistence through providing practical support (e.g. reminding 
patient to take hormonal therapy) while depression is often associated with social isolation and 
withdrawal from those who provide emotional support and assistance.(30, 31) 
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The risk factors identified in our systematic review and examined in our models provided limited 
evidence on identifying a subgroup of women towards whom strategies to in which to promote 
adherence or persistence with hormonal therapy might be targeted. There was some evidence 
that subgroups of younger and older women and those with no prior history of medication use 
may benefit from an intervention to support hormonal therapy MTB. Hence, despite a relatively 
large evidence base identifying and measuring demographic, clinical and treatment-related risk 
factors for hormonal therapy non-persistence our study suggests that these risk factors have 
limited predictive ability in identifying women at future risk of hormonal therapy non-persistence 
and are, therefore, of only minimal clinical utility in practice.(7, 8)  In order to better predict 
women at high risk of non-persistence, it is likely that these demographic, clinical and treatment-
related risk factors need to be combined with additional behavioural and psychological risk 
factors. For example, lower perceived necessity of treatment and a lack of belief in the efficacy 
of hormonal therapy have been shown to be associated with hormonal therapy non-persistence 
(32-34) and good physician-patient communication and collaborative decision-making has been 
found to be highly positively correlated with treatment adherence.(35) An assessment of these 
types of factors could potentially be undertaken at treatment initiation; such an assessment for 
non-persistence could include measuring patients beliefs about their hormonal therapy (e.g. 
risks, benefits, treatment efficacy) as well as assessing potential difficulties of remaining 
adherent with long-term therapy at treatment initiation.(36) Evaluation of the discriminative 
performance of models containing these types of factors, as well as demographic, clinical and 
treatment-related factors, is warranted.  
 
A consistent finding in the literature is that experience of side-effects is associated with 
hormonal therapy non-persistence.(8, 37-40)  However, their impact on breast cancer patients’ 
quality of life is often underestimated by clinicians.(41) Motivation to persist with hormonal 
therapy may be influenced by women’s acceptability of treatment side-effects and quality of life 
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preferences.(42) There is some evidence that switching hormonal therapy and developing 
patient self-management skills may potentially ease the side-effects burden and increase 
persistence with treatment.(43) A variety of treatments, including progestins, androgens, SSRIs 
and acupuncture have also shown efficacy in reducing hot flashes.(44, 45) Side-effects usually 
develop within the first few months of treatment initiation and could be evaluated and managed 
during initial clinic visits.(39) This information, alongside an assessment of women’s coping 
mechanisms could also be included in a baseline predictive model of non-persistence.  
 
Strengths and limitations 
This population-based cohort study, based on high quality prospectively collected prescription 
and cancer registry data, is the first to assess the discriminative performance of a large number 
of risk factors likely to be routinely available at baseline to the treating oncologist in predicting 
women at future risk of non-persistence. It is also one of only a small number of studies which 
have examined the impact of demographic, clinical and treatment-related risk factors on initial 
hormonal therapy persistence and persistence over 5 years – the minimum time frame of use 
recommended to achieve therapeutic benefit.(17, 21, 46)  There are, however, limitations to this 
study.  We were unable to determine the reasons for treatment non-adherence and non-
persistence and information was not available on a few demographic, clinical and treatment-
related variables which have previously been associated with non-persistence (e.g. presence of 
diabetes).(47) The cohort was based on a subset of women with medical card eligibility and may 
not represent MTB in women who pay for their prescriptions. However previous studies have 
found no association between monthly cost of hormonal therapy and non-persistence.(33, 37) 
The assessment of MTB was based upon prescription refill data and may therefore 
overestimate true adherence and persistence; however, use of prescription claims databases to 
estimate MTB has been validated in other studies.(48)  
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Implications & conclusions 
To date only a minority of published medication adherence enhancing interventions have 
demonstrated improved MTB or enhanced patient outcomes. These interventions were 
generally complex incorporating several different approaches and involving a range of health 
professionals.(49) Our findings indicate that demographic, clinical and treatment-related risk 
factors alone have limited predictive ability in identifying women at risk of hormonal therapy non-
persistence. Persistence and adherence to hormonal therapy is influenced by a number of 
factors; some of these related to the patient and their medical history (e.g. patient’s age, history 
of prior medication use) but others do not (e.g. beliefs about the risks and benefits of treatment, 
experience of adverse effects and a good patient-physician relationship). A combination of a 
baseline demographic and clinical and treatment-related risk-factor assessment, a baseline 
psychological (beliefs/perceptions of treatment) assessment and an early post initiation follow-
up assessment of side effects may be better at identifying those women at highest risk of 
hormonal therapy non-persistence and possibly at greatest likelihood of benefiting from 
intervention. Further studies of this integrated approach would be more informative than studies 
investigating and identifying individual risk factors. Such studies may ultimately improve 
hormonal therapy persistence and reduce breast cancer recurrence and mortality among 
women with breast cancer.  
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Table 1:  Multivariate relative risks (RR) and risk differences (RD) for the association 
between baseline risk factors and hormonal therapy non-persistence within 5 years of 
initiating treatment (N=3,415)  
Risk factor  Total 
N (%) 
Persistent 
N (%) 
Non-persistent 
N (%) 
Model 1: 
Adjusted RR 
(95% CI) 
Model 1: 
Adjusted RD  
(95% CI) 
Age at diagnosis <50 697 (20.4) 517 (74.2) 180 (25.8) 1.41 (1.16, 1.70) 0.07 (0.03, 0.11) 
 50-65 1309 (38.3) 1074 (82.1) 235 (17.9) Ref Ref 
 > 65 1409 (41.2) 1144 (81.2) 265 (18.8) 1.07 (0.89, 1.29) 0.02 (-0.02, 0.05) 
Marital status Other 1536 (44.9) 1207 (78.6) 329 (21.4) Ref Ref 
 Married 1879 (55.1) 1528 (81.3) 351 (18.7) 0.82 (0.70, 0.94) -0.04 (-0.07, -0.01) 
Occupational 
status 
Other 2715 (79.5) 2159 (79.5) 556 (20.5) Ref Ref 
 Homemaker 700 (20.5) 576 (82.3) 124 (17.7) 0.94 (0.78, 1.12) -0.01 (-0.05, 0.02) 
Residential 
location 
Urban 2102 (61.5) 1691 (80.5) 411 (19.5) Ref Ref 
 Rural 1313 (38.5) 1044 (79.5) 269 (20.5) 1.03 (0.88, 1.20) 0.01 (-0.02, 0.04) 
Smoking status Never 1724 (50.5) 1375 (79.8) 349 (20.2) Ref Ref 
 Current 789 (23.1) 639 (81.0) 150 (19.0) 0.91 (0.76, 1.09) -0.02 (-0.05, 0.01) 
 Former 417 (12.2) 332 (79.6) 85 (20.4) 1.03 (0.84, 1.27) 0.00 (-0.05, 0.04) 
 Unspecified 485 (14.2) 389 (80.2) 96 (19.8) 0.95 (0.78, 1.17) -0.01 (-0.05, 0.03) 
Deprivation 
category 
1 (Least 
Deprived) 
443 (12.9) 358 (80.8) 85 (19.2) Ref Ref 
 2 404 (11.8) 319 (79.0) 85 (21.0) 1.10 (0.84, 1.44) 0.02 (-0.03, 0.07) 
 3 452 (13.2) 365 (78.8) 96 (21.2) 1.10 (0.85, 1.42) 0.02 (-0.03, 0.07) 
 4 626 (18.3) 497 (79.4) 129 (20.6) 1.07 (0.84, 1.38) 0.02 (-0.03, 0.07) 
 5 (Most 
Deprived) 
1280(37.5) 1037 (81.0) 243 (19.0) 1.03 (0.82, 1.29) 0.01 (-0.04, 0.05) 
 Unspecified 210 (6.2) 168 (80.0) 42 (20.0) 1.06 (0.75, 1.49) 0.03 (-0.04, 0.09) 
Number of regular 
meds used pre-
diagnosis   
0 1212 (35.5) 913 (75.3) 299 (24.7) Ref Ref 
 1 - 4 842 (24.7) 685 (81.4) 157 (18.6) 0.73 (0.60, 0.88) -0.06 (-0.11, -0.03) 
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Risk factor  Total 
N (%) 
Persistent 
N (%) 
Non-persistent 
N (%) 
Model 1: 
Adjusted RR 
(95% CI) 
Model 1: 
Adjusted RD  
(95% CI) 
 ≥ 5 1361 (39.8) 1137 (83.5) 224 (16.5) 0.61 (0.50, 0.75) -0.09 (-0.13, -0.06) 
HRT use  No 2914 (85.3) 2312 (79.3) 602 (20.7) Ref Ref 
 Yes 501 (14.7) 423 (84.4) 78 (15.6) 0.90 (0.72, 1.14) -0.01 (-0.05, 0.02) 
Antidepressant 
use 
No 2713 (79.4) 2182 (80.4) 531 (19.6) Ref Ref 
 Yes 702 (20.6) 553 (78.8) 149 (21.2) 1.22 (1.04, 1.45) 0.04 (0.01, 0.08) 
ER/PR Status* ER+/PR+ 2250 (65.9) 1799 (80.0) 451 (20.0) Ref Ref 
 ER+/PR- 1058 (31.0) 850 (80.3) 208 (19.7) 1.01 (0.87, 1.18) 0.01 (-0.02, 0.04) 
 ER-/PR+ 107 (3.1) 86 (80.4) 21 (19.6) 0.92 (0.63, 1.37) -0.01 (-0.09, 0.07) 
HER2 Status Negative 2140 (62.7) 1732 (80.9) 408 (19.1) Ref Ref 
 Positive 391 (11.5) 309 (79.0) 82 (21.0) 1.04 (0.84, 1.28) 0.02 (-0.02, 0.07) 
 Unspecified 884 (25.9) 694 (78.5) 190 (21.5) 1.13 (0.96, 1.32) 0.03 (0.00, 0.06) 
Tumour Size < 2 cm 1438 (42.1) 1133 (78.8) 305 (21.2) Ref Ref 
 2-5 cm 1574 (46.1) 1276 (81.1) 298 (18.9) 0.92 (0.79, 1.07) -0.02 (-0.05, 0.01) 
 > 5 cm 385 (11.3) 314 (81.6) 71 (18.4) 0.89 (0.70, 1.15) -0.03 (-0.07, 0.02) 
 Unspecified 18 (0.53) 12 (66.7) 6 (33.3) 1.26 (0.64, 2.47) 0.07 (-0.15, 0.29) 
Nodal Status Negative 1651 (48.4) 1325 (80.3) 326 (19.8) Ref Ref 
 Positive 1639 (47.9) 1318 (80.4) 321 (19.6) 1.00 (0.86, 1.17 0.00 (-0.03, 0.03) 
 Unspecified 125 (3.7) 92 (73.6) 33 (26.4) 1.19 (0.85, 1.66) 0.05 (-0.03, 0.13) 
Tumour Grade Low 350 (10.2) 280 (80.0) 70 (20.0) Ref Ref 
 Intermediate 1805 (52.9) 1455 (80.6) 350 (19.4) 1.03 (0.82, 1.29) 0.01 (-0.04, 0.05) 
 High 986 (28.9) 788 (79.9) 198 (20.1) 1.05 (0.82, 1.35) 0.01 (-0.04, 0.06) 
 Unspecified 274 (8.0) 212 (77.4) 62 (22.6) 1.11 (0.82, 1.51) 0.03 (-0.03, 0.10) 
Surgery / 
Radiation 
Mastectomy 1793 (52.5) 1463 (81.6) 330 (18.4) Ref Ref 
 Breast 
conserving 
surgery + 
radiation 
1465 (42.9) 1154 (78.8) 311 (21.2) 1.16 (1.00, 1.34) 0.03 (0.00, 0.06) 
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Risk factor  Total 
N (%) 
Persistent 
N (%) 
Non-persistent 
N (%) 
Model 1: 
Adjusted RR 
(95% CI) 
Model 1: 
Adjusted RD  
(95% CI) 
 Breast 
conserving 
surgery - 
radiation 
157 (4.6) 118 (75.2) 39 (24.8) 1.36 (0.99, 1.86) 0.06 (-0.01, 0.13) 
Chemotherapy No 1659 (48.6) 1335 (80.5) 324 (19.5) Ref Ref 
 Yes 1756 (51.4) 1400 (79.7) 356 (20.3) 0.88 (0.74, 1.06) -0.02 (-0.05, 0.02) 
Hormonal Therapy AI 1627 (47.6) 1309 (80.5) 318 (19.5) Ref Ref 
 SERM 1788 (52.4) 1426 (79.8) 362 (20.2) 0.90 (0.78, 1.04) -0.01 (-0.04, 0.02) 
Women with stage I-III oestrogen (ER) or progesterone (PR) receptor positive breast cancer diagnosed 2001-2008, received tumour 
directed surgery and filled at least one prescription for hormonal therapy (selective estrogen receptor modulator, SERM; aromatase 
inhibitor, AI) within one year of breast cancer diagnosis and with 5 years of follow-up data. 
HRT= hormone replacement therapy, ER/PR status= estrogen receptor/progesterone receptor status, HER2 status= human 
epidermal growth factor receptor 2  
Relative risks (RR) and relative differences (RD) are mutually adjusted for all demographic, clinical or treatment-related baseline risk 
factors shown in the table. No significant collinearity was found between the risk factors. 
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Table 2:  Multivariate relative risks (RR) for the association between baseline risk factors 
and hormonal therapy non-persistence within 1 year of initiating treatment (N=6,609)  
Risk factor  Total 
N (%) 
Persistent 
N (%) 
Non-persistent 
N (%) 
Model 2:  
Adjusted RR 
(95% CI) 
Model 2: Adjusted 
RD  (95% CI) 
Age at 
diagnosis 
<50 1,539 (23.3) 1,437 (93.4) 102 (6.6) 1.07 (0.82, 1.40) 0.01 (-0.02, 0.02) 
 50-65 2,709 (41.0) 2,557 (94.4) 152 (5.6) Ref Ref 
 > 65 2,361 (35.7) 2,203 (93.3) 158 (6.7) 1.44 (1.11, 1.86) 0.02 (0.01, 0.04) 
Marital status Other 2,786 (42.2) 2,590 (93.0) 196 (7.0) Ref Ref 
 Married 3,823 (57.8) 3,607 (94.4) 216 (5.6) 0.79 (0.64, 0.96) -0.01 (-0.03, 0.00) 
Occupational 
status 
Other 5,166 (78.2) 4,841 (93.7) 325 (6.3) Ref Ref 
 Homemaker 1,433 (21.8) 1,356 (94.0) 87 (6.0) 1.08 (0.85, 1.36) 0.00 (-0.02, 0.02) 
Residential 
location 
Urban 4,087 (61.8) 3,842 (94.0) 245 (6.0) Ref Ref 
 Rural 2,522 (38.2) 2,355 (93.4) 167 (6.6) 1.16 (0.93, 1.42) 0.01 (-0.01, 0.03) 
Smoking 
status 
Never 3,213 (48.6) 3,021 (94.0) 192 (6.0) Ref Ref 
 Current 1,436 (21.7) 1,341 (93.4) 95 (6.6) 1.15 (0.90, 1.47) 0.01 (-0.01,0.03) 
 Former 795 (12.0) 741 (93.2) 54 (6.8) 1.14 (0.85, 1.52) 0.01 (-0.02, 0.03) 
 Unspecified 1,165 (17.6) 1,094 (93.9) 71 (6.1) 1.00 (0.76, 1.31) 0.00 (-0.02, 0.02) 
Deprivation 
category 
1 (Least 
Deprived) 
880 (13.3) 832 (94.6) 48 (5.4) Ref Ref 
 2 821 (12.4) 767 (93.4) 54 (6.6) 1.24 (0.85, 1.79) 0.01 (-0.02, 0.04) 
 3 861 (13.0) 802 (93.2) 59 (6.8) 1.31 (0.90, 1.88) 0.02 (-0.01, 0.05) 
 4 1,187 (18.0) 1,114 (93.9) 73 (6.1) 1.17 (0.82, 1.65) 0.01 (-0.02, 0.04) 
 5 (Most 
Deprived) 
2,427 (36.7) 2,269 (93.5) 158 (6.5) 1.34 (0.97, 1.83) 0.02 (-0.01,0.04) 
 Unspecified 433 (6.6) 413 (93.4) 20 (4.6) 0.99 (0.58, 1.67) 0.00 (-0.03, 0.04) 
Number of 
regular meds 
used pre-
diagnosis   
0 2,625 (39.7) 2,418 (92.1) 207 (7.9) Ref Ref 
 1 - 4 1,444 (21.9) 1,353 (93.7) 91 (6.3) 0.59 (0.44, 0.77) -0.03 (-0.05, -0.01) 
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Risk factor  Total 
N (%) 
Persistent 
N (%) 
Non-persistent 
N (%) 
Model 2:  
Adjusted RR 
(95% CI) 
Model 2: Adjusted 
RD  (95% CI) 
 ≥ 5 2,540 (38.4) 2,426 (95.5) 114 (4.5) 0.35 (0.26, 0.48) -0.5 (-0.07, -0.03) 
HRT use  No 5,683 (86.0) 5,325 (93.7) 358 (6.3) Ref Ref 
 Yes 926 (14.0) 872 (94.2) 54 (5.8) 1.25 (0.93, 1.68) 0.01 (-0.01, 0.03) 
Antidepressant 
use 
No 5,247 (79.4) 4,920 (93.8) 327 (6.2) Ref Ref 
 Yes 1,326 (20.6) 1,277 (93.8) 85 (6.2) 1.21 (0.95, 1.54) 0.01 (-0.01, 0.03) 
ER/PR Status* ER+/PR+ 4,550 (68.9) 4,278 (94.0) 272 (6.0) Ref Ref 
 ER+/PR- 1,911 (28.9) 1,782 (93.2) 129 (6.8) 1.13 (0.91, 1.39) 0.01 (-0.01, 0.03) 
 ER-/PR+ 148 (2.2) 137 (92.6) 11 (7.4) 1.15 (0.63, 2.03) 0.01 (-0.05, 0.06) 
HER2 Status Negative 4,791 (72.5) 4,514 (94.2) 277 (5.8) Ref Ref 
 Positive 799 (12.1) 750 (93.9) 49 (6.1) 1.01 (0.74, 1.36) -0.00 (-0.03, 0.02) 
 Unspecified 1,019  (15.4) 933 (91.6) 86 (8.4) 1.28 (1.01, 1.61) 0.02 (-0.01, 0.04) 
Tumour Size < 2 cm 2,845 (43.0) 2,665 (93.7) 180 (6.3) Ref Ref 
 2-5 cm 3,032 (45.9) 2,850 (94.0) 182 (6.0) 0.94 (0.76, 1.17) -0.01 (-0.02, 0.01) 
 > 5 cm 688 (10.4) 642 (93.3) 46 (6.7) 0.99 (0.70, 1.38) -0.00 (-0.03, 0.03) 
 Unspecified 44 (0.7) 40 (90.9) 4 (9.1) 1.07 (0.34, 2.64) 0.00 (-0.11, 0.11) 
Nodal Status Negative 3,196 (48.4) 3,010 (94.2) 186 (5.8) Ref Ref 
 Positive 3,207 (48.5) 3,003 (93.6) 204 (6.4) 1.11 (0.89, 1.37) 0.01 (-0.01, 0.02) 
 Unspecified 206 (3.1) 184 (89.3) 22 (10.7) 1.48 (0.96, 2.22) 0.04 (-0.01, 0.09) 
Tumour Grade Low 691 (10.5) 649 (93.9) 42 (6.1) Ref Ref 
 Intermediate 3,693 (55.9) 3,467 (93.9) 226 (6.1) 1.04 (0.75, 1.44) -0.00 (-0.03, 0.03) 
 High 1,863 (28.1) 1,759 (94.4) 104 (5.6) 0.93 (0.64, 1.34) -0.00 (-0.03, 0.02) 
 Unspecified 362 (5.5) 322 (88.9) 40 (11.1) 1.62 (1.09, 2.33) 0.04 (-0.01, 0.08) 
Surgery / 
Radiation 
Mastectomy 3,106 (47.0) 2,907 (93.6) 199 (6.4) Ref Ref 
 Breast 
conserving 
surgery + 
radiation 
3,239 (49.0) 3,052 (94.2) 187 (5.8) 0.95 (0.77, 1.18) -0.00 (-0.02, 0.020 
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Risk factor  Total 
N (%) 
Persistent 
N (%) 
Non-persistent 
N (%) 
Model 2:  
Adjusted RR 
(95% CI) 
Model 2: Adjusted 
RD  (95% CI) 
 Breast 
conserving 
surgery - 
radiation 
264 (4.0) 238 (90.2) 26 (9.8) 1.47 (0.97, 2.14) 0.03 (-0.01, 0.08) 
Chemotherapy No 3,024 (45.8) 2,827 (93.5) 197 (6.5) Ref Ref 
 Yes 3,585 (54.2) 3,370 (94.0) 215 (6.0) 0.78 (0.60, 1.01) -0.01 (-0.03, 0.01) 
Hormonal 
Therapy 
AI 3,343 (50.6) 3,146 (94.1) 197 (5.9) Ref Ref 
 SERM 3,266 (49.4) 3,051 (93.4) 215 (6.6) 1.07 (0.86, 1.31) 0.01 (-0.01, 0.03) 
Women with stage I-III oestrogen (ER) or progesterone (PR) receptor positive breast cancer diagnosed 2001-2008, received tumour 
directed surgery and filled at least one prescription for hormonal therapy (selective estrogen receptor modulator, SERM; aromatase 
inhibitor, AI) within one year of breast cancer diagnosis and with 1 year of follow-up data. 
HRT= hormone replacement therapy, ER/PR status= estrogen receptor/progesterone receptor status, HER2 status= human 
epidermal growth factor receptor 2  
Relative risks (RR) are mutually adjusted for all demographic, clinical or treatment-related baseline risk factors. No significant 
collinearity was found between the risk factors. 
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Figure 1: The receiver-operating characteristic (ROC) curve for hormonal therapy non-
persistence at 5 years (Model 1) 
 
* including all demographic, clinical or treatment-related baseline risk factors 
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Figure 2: The receiver-operating characteristic (ROC) curve for hormonal therapy non-
persistence at 1 year (Model 2) 
 
* including all demographic, clinical or treatment-related baseline risk factors 
 
 
 
 
 
 
 
 
 
 
